BIO 2014 Monday Round-Up: Let’s Make A Deal
This article was originally published in The Pink Sheet Daily
The annual BIO conference opened in San Diego with deals being announced at the outset and everyone enthusiastic about partnering.
You may also be interested in...
A PharmAsia News update shows Turkey has set a target to domestically manufacture 60% of the drug products used annually and 20% of medical device and equipment by an unspecified timeframe. The government also moved to offer more support into R&D for high-value biopharmaceutical products and sent a large ministerial delegation to the annual Bio Conference in San Diego as a signal of how important the sector is to its public health programs.
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.